| 1301 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Ukraine |
47 |
| 1302 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
USA |
64 |
| 1303 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
France |
67 |
| 1304 |
Apheresis |
Allogeneic |
Other Myelofibrosis/Myelosclerosis |
Hematology |
2025 |
Standard Therapy |
USA |
65 |
| 1305 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Germany |
58 |
| 1306 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2025 |
Standard Therapy |
Germany |
57 |
| 1307 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2025 |
Standard Therapy |
RUSSIAN FEDERATION |
22 |
| 1308 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Ukraine |
33 |
| 1309 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Slovakia |
41 |
| 1310 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Greece |
54 |
| 1311 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Ukraine |
46 |
| 1312 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Argentina |
26 |
| 1313 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
USA |
70 |
| 1314 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
59 |
| 1315 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
34 |
| 1316 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2025 |
Standard Therapy |
Norway |
53 |
| 1317 |
Apheresis |
Allogeneic |
Other Immune System |
Hematology |
2025 |
Standard Therapy |
USA |
19 |
| 1318 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2025 |
Standard Therapy |
Poland |
6 |
| 1319 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
USA |
68 |
| 1320 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
72 |
| 1321 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
64 |
| 1322 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
United Kingdom |
33 |
| 1323 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Italy |
63 |
| 1324 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Lithuania |
33 |
| 1325 |
Apheresis |
Autologous |
Central Nervous System Lymphoma |
Hematology |
2025 |
Standard Therapy |
Germany |
61 |
| 1326 |
Apheresis |
Allogeneic |
Acute lymphocytic leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
51 |
| 1327 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
64 |
| 1328 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
54 |
| 1329 |
Apheresis |
Autologous |
Testicular tumor |
Hematology |
2025 |
Standard Therapy |
Germany |
42 |
| 1330 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
52 |
| 1331 |
Apheresis |
Autologous |
T-cell lymphoma |
Hematology |
2025 |
Standard Therapy |
Germany |
49 |
| 1332 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
73 |
| 1333 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
62 |
| 1334 |
Apheresis |
Autologous |
Lymphoma Hodgkin |
Hematology |
2025 |
Standard Therapy |
Portugal |
39 |
| 1335 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
60 |
| 1336 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
70 |
| 1337 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
64 |
| 1338 |
Apheresis |
Autologous |
T-Cell Lymphoma |
Hematology |
2025 |
Standard Therapy |
Germany |
60 |
| 1339 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
62 |
| 1340 |
Apheresis |
Autologous |
Mantle Cell Lymphoma |
Hematology |
2025 |
Standard Therapy |
Germany |
60 |
| 1341 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
43 |
| 1342 |
Apheresis |
Allogeneic |
Myeofibrosis |
Hematology |
2025 |
Standard Therapy |
Poland |
37 |
| 1343 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Russia |
22 |
| 1344 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
NETHERLANDS |
66 |
| 1345 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
France |
57 |
| 1346 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
United Kingdom |
56 |
| 1347 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
78 |
| 1348 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
USA |
65 |
| 1349 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
53 |
| 1350 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Portugal |
41 |
| 1351 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
United Kingdom |
56 |
| 1352 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
22 |
| 1353 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
36 |
| 1354 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Canada |
65 |
| 1355 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
71 |
| 1356 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Sweden |
73 |
| 1357 |
Apheresis |
Allogeneic |
NK LGL Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
42 |
| 1358 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Italy |
29 |
| 1359 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
71 |
| 1360 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
68 |
| 1361 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Czechia |
64 |
| 1362 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
10 |
| 1363 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Brazil |
57 |
| 1364 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Lithuania |
21 |
| 1365 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Lithuania |
54 |
| 1366 |
Apheresis |
Allogeneic |
Richter Transformation From CLL |
Hematology |
2025 |
Standard Therapy |
Poland |
55 |
| 1367 |
Apheresis |
Allogeneic |
Richter Transformation From CLL |
Hematology |
2025 |
Standard Therapy |
Poland |
63 |
| 1368 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
68 |
| 1369 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
France |
55 |
| 1370 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Italy |
26 |
| 1371 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
NETHERLANDS |
63 |
| 1372 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
33 |
| 1373 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2025 |
Standard Therapy |
KAZAKHSTAN |
10 |
| 1374 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2025 |
Standard Therapy |
Italy |
53 |
| 1375 |
Apheresis |
Allogeneic |
Hodking Lymphoma |
Hematology |
2025 |
Standard Therapy |
Belgium |
62 |
| 1376 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
54 |
| 1377 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
66 |
| 1378 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Spain |
47 |
| 1379 |
Apheresis |
Allogeneic |
T-Cell Lymphoma |
Hematology |
2025 |
Standard Therapy |
Poland |
25 |
| 1380 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2025 |
Standard Therapy |
Portugal |
62 |
| 1381 |
Apheresis |
Autologous |
No Data |
Hematology |
2025 |
Standard Therapy |
Portugal |
65 |
| 1382 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
38 |
| 1383 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
60 |
| 1384 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
65 |
| 1385 |
Apheresis |
Autologous |
Diffuse Large B-Cell Lymphoma |
Hematology |
2025 |
Standard Therapy |
Germany |
61 |
| 1386 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
41 |
| 1387 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
73 |
| 1388 |
Apheresis |
Autologous |
T-Cell Lymphoma |
Hematology |
2025 |
Standard Therapy |
Germany |
49 |
| 1389 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
NETHERLANDS |
61 |
| 1390 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
United Kingdom |
2 |
| 1391 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Italy |
20 |
| 1392 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
5 |
| 1393 |
Apheresis |
Allogeneic |
Chronic Granulomatous Disease |
Hematology |
2025 |
Standard Therapy |
USA |
2 |
| 1394 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Slovakia |
56 |
| 1395 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
71 |
| 1396 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
USA |
60 |
| 1397 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
64 |
| 1398 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Czechia |
42 |
| 1399 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Germany |
63 |
| 1400 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Canada |
59 |